Hong-Hwa Chen

Hong-Hwa Chen


Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications

1 January 2020 in International Journal of Biological Sciences
Verified
Journal Article
Open access
YCYen-Ta Chen
Yen-Ta Chen
CHChi-Ruei Huang
Chi-Ruei Huang
CCChia-Lo Chang
Chia-Lo Chang
JCJohn Y. Chiang
John Y. Chiang
CLChi-Wen Luo
Chi-Wen Luo
HYHon-Kan Yip
Hon-Kan Yip
Background: This study assessed the expression of Jagged2 in human bladder cancer (BC) tested the hypothesis that melatonin (Mel) inhibited the tumorigenesis of BC cells mainly through downregulating the Notch/Jagged2 and PI3K/AKT/mTOR/MMPs(2&9) signaling pathways.

1 January 2021 in International Journal of Biological Sciences
Verified
Journal Article
Open access
YLYi-Chen Li
Yi-Chen Li
CCChih-Hung Chen
Chih-Hung Chen
CCChia-Lo Chang
Chia-Lo Chang
JCJohn Yi-Wu Chiang
John Yi-Wu Chiang
CCChi-Hsiang Chu
Chi-Hsiang Chu
HYHon-Kan Yip
Hon-Kan Yip
Colorectal cancer (CRC) is the third most common cancer worldwide. Colorectal carcinogenesis is frequently induced by hypoxia to trigger the reprogramming of cellular metabolism and gain of malignant phenotypes. Previously, hyperbaric oxygen (HBO) therapy and melatonin have been reported to alter the hypoxic microenvironment, resulting in inhibiting cancer cell survival. Accordingly, this study tested the hypothesis whether HBO and melatonin effectively inhibited CRC carcinogenesis. In vitro results indicated that melatonin therapy significantly suppressed the malignant phenotypes, including colony formation, growth, invasion, migration and cancer stemness with dose-dependent manners in CRC cell lines through multifaceted mechanisms. Similar to in vitro study, in vivo findings further demonstrated the melatonin, HBO and combined treatments effectively promoted apoptosis (cleaved-caspase 3/ cleaved-PARP) and arrested tumor proliferation, followed by inhibiting colorectal tumorigenesis in CRC xenograft tumor model. Moreover, melatonin, HBO and combined treatments modulated multifaceted mechanisms, including decreasing HIF-1α expression, alleviating AKT activation, repressing glycolytic metabolism (HK-2/PFK1/PKM2/LDH), restraining cancer stemness pathway (TGF-β/p-Smad3/Oct4/Nanog), reducing inflammation (p-NFκB/ COX-2), diminishing immune escape (PD-L1), and reversing expression of epithelial mesenchymal transition (E-cadherin/N-cadherin/MMP9). In conclusion, melatonin and HBO therapies suppressed colorectal carcinogenesis through the pleiotropic effects and multifaceted mechanisms, suggesting melatonin and HBO treatments could be novel therapeutic strategies for CRC treatment.

11 October 2021 in Cancers
Verified
Journal Article
Open access
PDF file
HSHarvey Yu-Li Su
Harvey Yu-Li Su
KTKai-Lung Tsai
Kai-Lung Tsai
TCTai-Jan Chiu
Tai-Jan Chiu
YLYueh-Ming Lin
Yueh-Ming Lin
KLKo-Chao Lee
Ko-Chao Lee
HHHung-Chih Hsu
Hung-Chih Hsu
(1) Background: To investigate the prognostic value of cancer-inflammation prognostic index (CIPI) in patients with metastatic colorectal cancer (mCRC) on regorafenib treatment; (2) Methods: Patients with mCRC who were given regorafenib as later-line treatment at Kaohsiung and Linkou Chang-Gung Memorial Hospital between November 2014 and January 2021 were consecutively enrolled. All relevant clinicopathologic, laboratory data and survival status were recorded. Independent prognostic factors were determined by the multivariate Cox regression method; (3) Results: In total, 106 patients in the training cohort and 250 in the validation cohort were enrolled. The median OS for patients with CIPI ≥ 300 and < 300 in the training cohort was 3.8 and 9.0 months, respectively (hazard ratio (HR) 2.78, 95% confidence interval (CI) 1.82–4.23; p < 0.0001). Time to regorafenib, liver metastasis and CIPI were independent factors by multivariate Cox regression analyses. A new scoring model demonstrated a good discriminatory ability to risk stratification of a patient’s survival; (4) Conclusions: We identified CIPI as a novel serum marker highly associated with overall survival in patients with mCRC receiving regorafenib treatment. Further confirmatory studies are warranted.

1 July 2001 in Archives of Surgery
Verified
Journal Article
Open access
PDF file
HCHong-Hwa Chen
Hong-Hwa Chen
WTWen Sy Tsai
Wen Sy Tsai
CYChien-Yuh Yeh
Chien-Yuh Yeh
JWJeng-Yi Wang
Jeng-Yi Wang
RTReiping Tang
Reiping Tang
INCISIONAL WOUND closures have traditionally been divided into the categories of thread and threadless sutures.1 Linen strips were first used for the closure of wounds in Egypt in 1600 BC.2 There has been a revival of threadless closure in recent decades. Wound closure with adhesive tape has several advantages over the use of sutures, including a less pronounced inflammation reaction (caused by suture materials), lower infection rates, no risk of abscess development at the location of stitches, and greater tensile strength when wounds are sutured late in the healing process (20-150 days).3-6 Additional advantages of taped skin closure compared with sutured skin closure include lower cost, reduction in operating room time, and improved cosmetic results.7,8 Although the scientific basis for selecting taped skin closure for abdominal wounds has been documented,9 the technique has not been widely used for this purpose. This may be due to fears of a wider scar, the weaker supporting strength of the tape, and/or an increased rate of wound complications, particularly in clean-contaminated wounds. Conolly et al10 reported a lower rate of infection for the taped wounds (3.8% vs 14% for the sutured wounds) in those patients with clean-contaminated wounds. In the study by Webster and Davis,2 the infection rate for the taped wounds (11.1%) was higher than for the sutured wounds (8.4%). To test the efficacy of skin closure using paper tape in the clean-contaminated abdominal wound, we conducted this prospective study to compare taped with sutured wounds in terms of the duration of skin closure, wound complication rate, and cosmetic appearance of the scar at 6 months after operation.

Verified
Journal Article
Open access
PDF file
CYChih-Chao Yang
Chih-Chao Yang
FCFei-Chi Chuang
Fei-Chi Chuang
CCChia-Lo Chang
Chia-Lo Chang
CHChi-Ruei Huang
Chi-Ruei Huang
HCHong-Hwa Chen
Hong-Hwa Chen
CYCheng-Ta Yang
Cheng-Ta Yang
This study investigated whether melatonin (Mel) would promote cisplatin to suppress the proliferation and growth of bladder cancer (BC) cells by inhibiting cellular prion protein (PrPC)-mediated cell stress and cell proliferation signaling. An immunohistochemical staining of tissue arrays from BC patients demonstrated that the PrPC expression was significantly upregulated from stage I to III BC (p < 0.0001). The BC cellline of T24 was categorized into G1 (T24), G2 (T24 + Mel/100 μM), G3 (T24+cisplatin/6 μM), G4 (PrPC overexpression in T24 (i.e., PrPC-OE-T24)), G5 (PrPC-OE-T24+Mel), and G6 (PrPC-OE-T24+cisplatin). When compared with a human uroepithelial cell line (SV-HUC-1), the cellular viability/wound healing ability/migration rate were significantly increased in T24 cells (G1) and further significantly increased in PrPC-OE-T24 cells (G4); and they were suppressed in Mel (G2/G5) or cisplatin (G3/G6) treatment (all p < 0.0001). Additionally, the protein expressions of cell proliferation (PI3K/p-Akt/p-m-TOR/MMP-9/PrPC), cell cycle/mitochondrial functional integrity (cyclin-D1/clyclin-E1/ckd2/ckd4/mitochondrial-cytochrome-C/PINK1), and cell stress (RAS/c-RAF/p-MEK1/2, p-ERK1/2) markers showed a similar pattern of cell viability among the groups (all p < 0.001). After the BC cell line of UMUC3 was implanted into nude mouse backs, by day 28 mthe BC weight/volume and the cellular levels of PrPC/MMP-2/MMP-9 were significantly, gradually reduced from groups one to four (all p < 0.0001). The protein expressions of cell proliferation (PI3K/p-Akt/p-m-TOR/MMP-9/PrPC), cell cycle/mitophagy (cyclin-D1/clyclin-E1/ckd2/ckd4/PINK1), and cell stress (RAS/c-RAF/p-MEK1,2/p-ERK1,2) signaling were significantly, progressively reduced from groups one to four, whereas the protein expressions of apoptotic (Mit-Bax/cleaved-caspase-3/cleaved-PARP) and oxidative stress/mitochondrial damaged (NOX-1/NOX-2/cytosolic-cytochrome-C/p-DRP1) markers expressed an opposite pattern of cell proliferation signaling among the groups (all p < 0.0001). Mel-cisplatin suppressed BC cell growth/proliferation via inhibiting the PrPC in upregulating the cell proliferation/cell stress/cell cycle signaling.